University of South Alabama Mitchell Cancer Institute

Summary

University of South Alabama Mitchell Cancer Institute is a medical facility located in Mobile, Alabama. This center is recognized for care of Breast Cancer, Ovarian Cancer, Pancreatic Cancer, Breast cancer, Cancer and other specialties. University of South Alabama Mitchell Cancer Institute is involved with conducting 130 clinical trials across 239 conditions. There are 13 research doctors associated with this hospital, such as Moh'd Khushman, Ahmed Abdalla, Teja Poosarla, MD, and Jennifer Scalici,, MD.

Top PIs

Clinical Trials running at University of South Alabama Mitchell Cancer Institute

Ovarian Cancer

Breast Cancer

Cancer

Endometrial Cancer

Pancreatic Cancer

Breast cancer

Fallopian Tube Cancer

Solid Tumors

Non-Small Cell Lung Cancer

Parkinson's disease

Mirvetuximab + Bevacizumab

for Ovarian Cancer

GLORIOSA is a Phase 3 multicenter, open label study designed to evaluate the safety and efficacy of mirvetuximab Soravtansine + Bevacizumab as maintenance therapy in participants with platinum-sensitive ovarian, primary peritoneal or fallopian tube cancers with high folate receptor-alpha (FRα) expression.

Recruiting

2 awards

Phase 3

Targeted Therapy

for Solid Tumors

This ComboMATCH patient screening trial is the gateway to a coordinated set of clinical trials to study cancer treatment directed by genetic testing. Patients with solid tumors that have spread to nearby tissue or lymph nodes (locally advanced) or have spread to other places in the body (advanced) and have progressed on at least one line of standard systemic therapy or have no standard treatment that has been shown to prolong overall survival may be candidates for these trials. Genetic tests look at the unique genetic material (genes) of patients' tumor cells. Patients with some genetic changes or abnormalities (mutations) may benefit from treatment that targets that particular genetic mutation. ComboMATCH is designed to match patients to a treatment that may work to control their tumor and may help doctors plan better treatment for patients with locally advanced or advanced solid tumors.

Recruiting

1 award

Phase 2

17 criteria

Neratinib or Neratinib + Palbociclib

for Cancer

This phase II ComboMATCH treatment trial compares the effect of neratinib to the combination of neratinib and palbociclib in treating patients with HER2 positive solid tumors. Neratinib and palbociclib are in a class of medications called kinase inhibitors. They work by blocking the action of an abnormal protein that signals cancer cells to multiply. This helps slow or stop the spread of tumor cells. Giving neratinib and palbociclib in combination may shrink or stabilize cancers that over-express a specific biomarker called HER2.

Recruiting

1 award

Phase 2